Healthcare [ 12/13 ] | Biotechnology [ 116/164 ]
NASDAQ | Common Stock
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States.
Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.
The company is headquartered in West Conshohocken, Pennsylvania.
Reported date | EPSChange YoY | EstimateSurprise |
---|---|---|
May 7, 24 | -7.38 Decreased by -74.39% | -6.28 Decreased by -17.46% |
Mar 14, 24 | -5.68 Decreased by -14.06% | -5.28 Decreased by -7.58% |
Nov 6, 23 | -5.34 Decreased by -12.42% | -4.93 Decreased by -8.32% |
Aug 8, 23 | -4.69 Decreased by -13.29% | -4.58 Decreased by -2.40% |
May 9, 23 | -4.23 Decreased by -25.89% | -4.94 Increased by +14.37% |
Feb 23, 23 | -4.98 Decreased by -31.75% | -4.56 Decreased by -9.21% |
Nov 3, 22 | -4.75 Decreased by -25.33% | -4.15 Decreased by -14.46% |
Aug 4, 22 | -4.14 Decreased by -11.29% | -3.70 Decreased by -11.89% |
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Dec 31, 23 | 0.00 Decreased by N/A% | -112.19 M Decreased by -28.09% | Decreased by N/A% Decreased by N/A% |
Sep 30, 23 | 0.00 Decreased by N/A% | -98.74 M Decreased by -19.40% | Decreased by N/A% Decreased by N/A% |
Jun 30, 23 | 0.00 Decreased by N/A% | -85.80 M Decreased by -19.98% | Decreased by N/A% Decreased by N/A% |
Mar 31, 23 | 0.00 Decreased by N/A% | -77.79 M Decreased by -35.09% | Decreased by N/A% Decreased by N/A% |
Dec 31, 22 | 0.00 Decreased by -100.00% | -87.59 M Decreased by -35.69% | Decreased by N/A% Decreased by N/A% |
Sep 30, 22 | 0.00 Decreased by -100.00% | -82.70 M Decreased by -31.06% | Decreased by N/A% Decreased by N/A% |
Jun 30, 22 | 0.00 Decreased by -100.00% | -71.51 M Decreased by -15.99% | Decreased by N/A% Decreased by N/A% |
Mar 31, 22 | 0.00 Decreased by -100.00% | -57.59 M Decreased by -9.59% | Decreased by N/A% Decreased by N/A% |